SCHEMBL1384286

SCHEMBL1384286

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4noc(N)c34)cc2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.73
FLT3 P36888 13/20 0.73
KIT P10721 11/20 0.73
FLT1 P17948 5/20 0.65
CSF1R P07333 3/20 0.65
FLT4 P35916 3/20 0.65
PDGFRB P09619 3/20 0.65
TEK Q02763 2/20 0.65
LCK P06239 2/20 0.65
ROCK2 O75116 2/20 0.65
CDK1 P06493 2/20 0.65
AXL P30530 2/20 0.65
FRK P42685 2/20 0.65
BLK P51451 2/20 0.65
CSNK1G2 P78368 2/20 0.65
ROCK1 Q13464 2/20 0.65
AURKB Q96GD4 2/20 0.65
HIPK2 Q9H2X6 2/20 0.65
CLK4 Q9HAZ1 2/20 0.65
CSNK1G1 Q9HCP0 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4737316 0.88 KDR (0.68) KDRFLT3KITFLT1CSF1R
SCHEMBL4736275 0.87 KDR (0.71) KDRFLT3KITFLT1CSF1R
SCHEMBL1384952 0.87 KDR (0.74) KDRFLT3KITFLT1CSF1R
SCHEMBL4740129 0.86 KDR (0.75) KDRFLT3KITFLT1CSF1R
SCHEMBL1383479 0.86 KDR (0.70) KDRFLT3KITFLT1CSF1R
SCHEMBL4740182 0.85 KDR (0.72) KDRFLT3KITFLT1CSF1R
SCHEMBL1382188 0.85 KDR (0.70) KDRFLT3KITFLT1CSF1R
SCHEMBL420457 0.85 KIT (1.00) KDRFLT3KITFLT1CSF1R
SCHEMBL4740470 0.85 KDR (0.76) KDRFLT3KITFLT1CSF1R
SCHEMBL1382612 0.83 KDR (0.68) KDRFLT3KITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4810427-B2 2011-11-09 JP claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP claimed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed